Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60060 |
Name | non-Hodgkin lymphoma |
Definition | A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS mutant | Trametinib | non-Hodgkin lymphoma | resistant | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00576654 | Phase I | Irinotecan Veliparib | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT00577278 | Phase II | Ibritumomab tiuxetan Methotrexate + Sirolimus + Tacrolimus Rituximab Fludarabine + Melphalan | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | Completed | USA | 0 |
NCT00602693 | Phase I | Sirolimus Allopurinol + Cyclophosphamide + Fludarabine | T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer | Completed | USA | 0 |
NCT00671112 | Phase I | Bortezomib + Everolimus | Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma | Terminated | USA | 0 |
NCT00740805 | Phase I | Aldoxorubicin + Cyclophosphamide + Veliparib | Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT00854152 | Phase I | Apitolisib | A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma | Completed | USA | GBR | 0 |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT01032148 | Phase I | Panobinostat | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT01058239 | Phase II | Bortezomib + Rituximab | Bortezomib Plus Rituximab for EBV+ PTLD | Completed | USA | 0 |
NCT01076543 | Phase Ib/II | Lenalidomide + Temsirolimus | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01162551 | Phase II | Methotrexate + Sirolimus | Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma | Completed | USA | 0 |
NCT01187810 | Phase I | Fenretinide Cytarabine Methotrexate | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Terminated | USA | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01306643 | Phase Ib/II | Idelalisib | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | Completed | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | ITA | FRA | AUS | 1 |
NCT01321346 | Phase I | Cytarabine Panobinostat | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT01324180 | Phase I | Metformin Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Sulfate | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | Completed | USA | 0 |
NCT01333046 | Phase I | MultiTAA-specific T cells Azacitidine + MultiTAA-specific T cells | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (TACTAL) | Active, not recruiting | USA | 0 |
NCT01353625 | Phase I | CC-115 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | Completed | USA | FRA | ESP | DEU | 0 |
NCT01408043 | Phase I | Etoposide + Filgrastim + Plerixafor | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | Terminated | USA | 0 |
NCT01421524 | Phase I | CC-122 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Completed | USA | ITA | FRA | ESP | BEL | 0 |
NCT01581541 | Phase I | PU-H71 | PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment | Terminated | USA | 0 |
NCT01592370 | Phase Ib/II | Nivolumab Daratumumab + Nivolumab Daratumumab Ipilimumab + Nivolumab Daratumumab + Dexamethasone + Nivolumab + Pomalidomide Lirilumab + Nivolumab | An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma | Completed | USA | POL | ITA | GRC | FRA | BEL | 0 |
NCT01609816 | Phase Ib/II | Dasatinib | Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant | Terminated | USA | 0 |
NCT01614197 | Phase I | Etoposide Cyclophosphamide Prednisone Cytarabine Temsirolimus Methotrexate | A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | Completed | USA | CAN | AUS | 0 |
NCT01621477 | Phase II | Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | Terminated | USA | 0 |
NCT01634217 | Phase I | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | Completed | USA | 0 | |
NCT01660451 | Phase II | Copanlisib | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | Completed | USA | TUR | SWE | POL | NZL | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BGR | BEL | AUT | AUS | 5 |
NCT01686165 | Phase II | Belinostat Rituximab | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01701986 | Phase Ib/II | Tacrolimus Rituximab Filgrastim Mycophenolate mofetil anti-thymocyte globulin Busulfan + Clofarabine + Gemcitabine | Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas | Completed | USA | 0 |
NCT01719250 | Phase I | Buparlisib | Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT01732913 | Phase III | Idelalisib Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | AUS | 6 |
NCT01732926 | Phase III | Idelalisib Bendamustine + Rituximab | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | Terminated | USA | SWE | POL | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 3 |
NCT01742988 | Phase Ib/II | Bendamustine + CUDC-907 + Rituximab CUDC-907 + Rituximab CUDC-907 CUDC-907 + Venetoclax | Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma | Completed | USA | 0 |
NCT01745354 | Phase I | SD-101 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | Terminated | USA | 0 |
NCT01746849 | Phase II | Leuprolide Cyclophosphamide Thiotepa Palifermin | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01811368 | Phase II | anti-thymocyte globulin + Ibritumomab tiuxetan + Rituximab Cyclosporine + Mycophenolate mofetil | Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01871675 | Phase I | Rituximab Duvelisib Bendamustine | Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | Completed | USA | 0 |
NCT01882803 | Phase II | Duvelisib | A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) | Completed | USA | ITA | HUN | GBR | FRA | ESP | CZE | CAN | BGR | BEL | 2 |
NCT01905813 | Phase I | Dezapelisib + Itacitinib Dezapelisib | Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies | Active, not recruiting | USA | 0 |
NCT01949883 | Phase I | CPI-0610 | A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma | Completed | 0 | |
NCT01953692 | Phase I | Pembrolizumab | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Completed | 0 | |
NCT01983969 | Phase Ib/II | Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | Completed | USA | 0 |
NCT01992653 | Phase I | Cyclophosphamide + Doxorubicin + Prednisone Rituximab Polatuzumab vedotin-piiq Obinutuzumab | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | Completed | USA | FRA | 0 |
NCT01994382 | Phase I | Cerdulatinib | Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma | Completed | USA | 0 |
NCT02000934 | Phase I | Mivavotinib | A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies | Completed | USA | ITA | GBR | ESP | 0 |
NCT02018861 | Phase I | Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib | A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies | Completed | USA | 0 |
NCT02028455 | Phase Ib/II | Anti-CD19CAR-CD28-CD3zeta-EGFRt T-cells | A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia | Active, not recruiting | USA | 0 |
NCT02043587 | Phase II | Rituximab Pegaspargase Methotrexate Cytarabine Leucovorin Cyclophosphamide Dasatinib Daunorubicin Vincristine Sulfate Etoposide | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | Terminated | USA | 0 |
NCT02055820 | Phase I | Venetoclax Rituximab Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Sulfate Obinutuzumab | A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma | Completed | USA | NLD | ITA | HUN | FRA | ESP | CZE | CAN | AUT | AUS | 0 |
NCT02061761 | Phase Ib/II | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | Completed | USA | CAN | 0 |
NCT02082977 | Phase I | GSK126 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma | Terminated | USA | GBR | FRA | 0 |
NCT02091063 | Phase Ib/II | Ricolinostat | ACY-1215 for Relapsed/Refractory Lymphoid Malignancies | Terminated | USA | 0 |
NCT02098109 | Phase II | Plerixafor Filgrastim | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT02104427 | Phase II | Burixafor Filgrastim | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | Completed | USA | 0 |
NCT02110563 | Phase I | DCR-MYC | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma | Terminated | USA | 0 |
NCT02130869 | Phase I | Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02142530 | Phase I | Belinostat Carfilzomib | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | Completed | USA | 0 |
NCT02155582 | Phase I | Copanlisib | Copanlisib Pharmacodynamic Study | Completed | GBR | FRA | BEL | 0 |
NCT02180711 | Phase I | Acalabrutinib | An Open-label, Phase 1b Study of ACP 196 in Subjects With Follicular Lymphoma | Active, not recruiting | USA | ITA | CAN | 0 |
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02204982 | Phase III | Duvelisib Rituximab | Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R) | Terminated | POL | ITA | FRA | AUS | 0 |
NCT02281279 | Phase Ib/II | Lenalidomide + Rituximab + Romidepsin | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | Withdrawn | 0 | |
NCT02287311 | Phase I | LMP/BARF1/EBNA1-specific cytotoxic T lymphocytes Cyclophosphamide + Fludarabine | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | Recruiting | USA | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Completed | USA | CAN | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02329847 | Phase Ib/II | Ibrutinib + Nivolumab | Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies | Completed | USA | TUR | POL | ISR | ESP | AUS | 0 |
NCT02343666 | Phase I | Filgrastim Carmustine Plerixafor O6-benzylguanine | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | Withdrawn | USA | 0 |
NCT02348216 | Phase Ib/II | axicabtagene ciloleucel | A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) | Completed | USA | NLD | ISR | FRA | DEU | CAN | 0 |
NCT02361346 | Phase Ib/II | MT-3724 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) | Terminated | USA | POL | ISR | ESP | CAN | 5 |
NCT02367040 | Phase III | Rituximab Copanlisib | Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) | Active, not recruiting | USA | TUR | SVK | ROU | POL | NZL | LTU | ITA | IRL | HUN | GRC | FRA | ESP | DEU | BRA | BGR | BEL | AUT | AUS | ARG | 17 |
NCT02367196 | Phase I | CC-90002 + Rituximab CC-90002 | A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | Completed | USA | ESP | 0 |
NCT02408042 | Phase Ib/II | Rituximab Carboplatin + Etoposide + Ifosfamide Pembrolizumab Brentuximab vedotin | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | Withdrawn | USA | 0 |
NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02529813 | Phase I | Cyclophosphamide + Fludarabine + Tisagenlecleucel | CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | Completed | USA | 0 |
NCT02541604 | Phase I | Atezolizumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors | Terminated | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02576496 | Phase I | Tinostamustine | Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Completed | USA | NLD | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02594384 | Phase I | LAM-002A | A Phase I Dose Escalation Study A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) | Completed | USA | 0 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Completed | USA | 0 |
NCT02611323 | Phase Ib/II | Polatuzumab vedotin-piiq + Rituximab + Venetoclax Obinutuzumab + Polatuzumab vedotin-piiq + Venetoclax | A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) | Completed | USA | ITA | AUS | 0 |
NCT02613598 | Phase I | Bortezomib + Ruxolitinib | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | Completed | USA | 0 |
NCT02635672 | Phase I | VIP152 | Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer | Completed | USA | ESP | 1 |
NCT02651662 | Phase I | Cemiplimab Cemiplimab + Odronextamab | Study of REGN2810 and REGN1979 in Patients With Lymphoma | Recruiting | USA | POL | ISR | ESP | DEU | 0 |
NCT02662296 | Phase II | Idelalisib Ibrutinib | Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant | Withdrawn | USA | 0 |
NCT02663297 | Phase I | ATLCAR.CD30 cells | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | Active, not recruiting | USA | 0 |
NCT02690545 | Phase Ib/II | ATLCAR.CD30 cells | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | Recruiting | USA | 0 |
NCT02701673 | Phase Ib/II | Azacitidine Pyridoxine Gemcitabine Belinostat Busulfan Melphalan | Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma | Withdrawn | 0 | |
NCT02702492 | Phase I | KPT-9274 KPT-9274 + Niacin | PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA) | Terminated | USA | CAN | 0 |
NCT02703272 | Phase III | Ibrutinib Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine Sulfate | A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma | Terminated | USA | TUR | SWE | ROU | POL | NLD | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | 4 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02732275 | Phase I | DS-3201b | DS-3201b in Participants With Lymphomas | Active, not recruiting | USA | 1 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Completed | USA | NLD | FRA | CAN | 0 |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Active, not recruiting | USA | 0 |
NCT02797470 | Phase Ib/II | Carmustine + CCR5 shRNA/TRIM5a/TAR decoy-transduced CD34+ HPCs + Cytarabine + Etoposide + Melphalan | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT02867618 | Phase Ib/II | Carfilzomib + Umbralisib | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | Terminated | USA | 0 |
NCT02875067 | Phase Ib/II | Lenalidomide + Pembrolizumab | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | Terminated | USA | 0 |
NCT02875223 | Phase I | CC-90011 | A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas | Terminated | ITA | GBR | FRA | ESP | 1 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02917083 | Phase I | ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30) | Recruiting | USA | 0 |
NCT02925234 | Phase II | Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab | The Drug Rediscovery Protocol (DRUP Trial) (DRUP) | Recruiting | NLD | 0 |
NCT02953509 | Phase Ib/II | Hu5F9-G4 + Rituximab | Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Terminated | USA | GBR | AUS | 0 |
NCT02954406 | Phase I | Lenalidomide + Mivavotinib Ibrutinib + Mivavotinib Gemcitabine + Mivavotinib Bendamustine + Mivavotinib + Rituximab Bendamustine + Mivavotinib | A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma | Terminated | USA | CAN | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02961816 | Phase II | Pyridoxine Busulfan + Gemcitabine + Melphalan + Panobinostat Dexamethasone + Filgrastim + Palifermin + Rituximab | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma | Withdrawn | 0 | |
NCT02973113 | Phase I | EB-VST cells + Nivolumab | Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE) | Completed | USA | 0 |
NCT02978235 | Phase Ib/II | TAS4464 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma | Terminated | USA | 0 |
NCT03015896 | Phase Ib/II | Lenalidomide + Nivolumab | Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03019666 | Phase I | Allogeneic NAM NK cells Cyclophosphamide + Fludarabine | Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | Completed | USA | 0 |
NCT03035331 | Phase Ib/II | Pembrolizumab | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03036904 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Rituximab + Venetoclax + Vincristine Sulfate | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R) | Completed | USA | 0 |
NCT03056339 | Phase Ib/II | Cyclophosphamide + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | Completed | USA | 0 |
NCT03081910 | Phase I | CD5 CAR-T cells Cyclophosphamide + Fludarabine | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | Recruiting | USA | 0 |
NCT03082209 | Phase I | ABBV-621 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies | Completed | USA | NLD | ESP | 1 |
NCT03105336 | Phase II | axicabtagene ciloleucel | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5) | Active, not recruiting | USA | FRA | 0 |
NCT03119467 | Phase I | RP4010 | Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Terminated | USA | AUS | 0 |
NCT03133221 | Phase II | Idelalisib | 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03147885 | Phase Ib/II | Selinexor | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03153462 | Expanded access | axicabtagene ciloleucel + Cyclophosphamide + Fludarabine | Axicabtagene Ciloleucel Expanded Access Study | Approved for marketing | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03188965 | Phase I | Elimusertib | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CHE | CAN | 3 |
NCT03206671 | Phase III | Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab Cyclophosphamide + Cytarabine + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Rituximab + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Etoposide + Ifosfamide + Methotrexate + Prednisolone + Vincristine Sulfate | Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents (B-NHL 2013) | Recruiting | SWE | NOR | FIN | DNK | DEU | CZE | CHE | AUT | 0 |
NCT03207256 | Phase II | Ublituximab + Umbralisib Umbralisib | Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | Terminated | USA | 0 |
NCT03210662 | Phase II | Pembrolizumab | Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL) | Active, not recruiting | USA | 0 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | POL | NZL | FRA | ESP | AUS | 4 |
NCT03213652 | Phase II | Ensartinib | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03213665 | Phase II | Tazemetostat | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213678 | Phase II | LY3023414 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213691 | Phase II | Selumetinib | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03218683 | Phase I | AZD5991 | Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. | Terminated | USA | 0 |
NCT03220035 | Phase II | Vemurafenib | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03233204 | Phase II | Olaparib | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | Completed | USA | 1 |
NCT03258567 | Phase II | Nivolumab | Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas | Recruiting | USA | 0 |
NCT03259503 | Phase Ib/II | Busulfan Olaparib Vorinostat Palifermin Gemcitabine Melphalan Dexamethasone Pyridoxine Rituximab | Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas | Active, not recruiting | USA | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03283137 | Phase I | Pembrolizumab + Umbralisib | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL | Active, not recruiting | USA | 0 |
NCT03297424 | Phase Ib/II | PLX2853 | A Study of PLX2853 in Advanced Malignancies. | Completed | USA | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) | Recruiting | CAN | 0 |
NCT03352765 | Phase I | Bendamustine + Melphalan + Rituximab | A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients | Active, not recruiting | USA | 0 |
NCT03357627 | Phase I | Mivavotinib + Venetoclax | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | Completed | USA | DEU | CAN | 0 |
NCT03357757 | Phase II | Avelumab + Valproic acid | Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) | Active, not recruiting | CAN | 0 |
NCT03366272 | Phase II | Gemcitabine + Nivolumab + Oxaliplatin + Rituximab Gemcitabine + Oxaliplatin + Rituximab | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients (NIVEAU) | Active, not recruiting | POL | NLD | ISR | FRA | DEU | BEL | AUT | 1 |
NCT03379493 | Phase I | Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma | Terminated | USA | 0 | |
NCT03424603 | Phase I | STRO-001 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Completed | USA | 0 |
NCT03432741 | Phase I | Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer | Suspended | USA | 0 |
NCT03467373 | Phase I | Tocilizumab Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate Glofitamab-gxbm Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Obinutuzumab + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Glofitamab-gxbm + Prednisone + Rituximab + Vincristine Sulfate | A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03484702 | Phase II | Lisocabtagene maraleucel | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) | Completed | NLD | ITA | GBR | FRA | FIN | ESP | DEU | CHE | BEL | AUT | 1 |
NCT03505762 | Phase II | Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate | Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment | Active, not recruiting | USA | 0 |
NCT03526250 | Phase II | Palbociclib | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | Completed | USA | 1 |
NCT03527147 | Phase I | Acalabrutinib + Danvatirsen Acalabrutinib + Ceralasertib | Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) | Completed | USA | GBR | 0 |
NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03571568 | Phase Ib/II | BI-1206 + Rituximab | A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | SWE | POL | ESP | DEU | BRA | 0 |
NCT03579888 | Phase I | CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells + Cyclophosphamide + Fludarabine | CD19-Specific T Cells Post AlloSCT | Terminated | USA | 0 |
NCT03583424 | Phase Ib/II | Carmustine + Cytarabine + Etoposide + Melphalan + Venetoclax | Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma | Unknown status | USA | 0 |
NCT03598608 | Phase Ib/II | MK-4280 + Pembrolizumab | Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | Recruiting | USA | ITA | ISR | DEU | CAN | AUS | 0 |
NCT03677141 | Phase Ib/II | Tocilizumab Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone + Vincristine Sulfate | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | Completed | USA | POL | FRA | ESP | AUT | 1 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03707093 | Phase I | ADG106 | Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma | Completed | USA | 0 |
NCT03713580 | Phase I | Carmustine + Cytarabine + Etoposide + Melphalan + Venetoclax | Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Active, not recruiting | USA | SWE | POL | ITA | GBR | FRA | CHE | AUS | 2 |
NCT03744676 | Phase II | Lisocabtagene maraleucel | A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | Completed | USA | 0 |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03765177 | Phase Ib/II | CLIC-1901 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies (CLIC-01) | Recruiting | CAN | 0 |
NCT03772288 | Phase I | Mivavotinib + NKTR-214 | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) | Withdrawn | USA | CAN | 0 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | POL | ITA | FRA | FIN | ESP | 0 |
NCT03789097 | Phase Ib/II | CDX-301 + Pembrolizumab + Poly ICLC | Vaccination With Flt3L, Radiation, and Poly-ICLC | Recruiting | USA | 0 |
NCT03797261 | Phase I | AMG 176 + Venetoclax | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | Terminated | USA | DEU | AUS | 0 |
NCT03809624 | Phase II | INBRX-105 INBRX-105 + Pembrolizumab | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB) | Terminated | USA | 0 |
NCT03829254 | Phase Ib/II | NUC-7738 NUC-7738 + Pembrolizumab | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Recruiting | GBR | 0 |
NCT03853616 | Phase Ib/II | MB-CART19.1 | MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | Recruiting | DEU | 0 |
NCT03884998 | Phase I | Copanlisib + Nivolumab | Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma | Active, not recruiting | USA | 0 |
NCT03885947 | Phase I | Cyclophosphamide + Fludarabine + Thiotepa | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | Completed | USA | 0 |
NCT03893682 | Phase I | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |
NCT03900598 | Phase I | JNJ-67856633 | A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Active, not recruiting | USA | ITA | ISR | GRC | GBR | FRA | ESP | DEU | AUS | 3 |
NCT03921879 | Phase I | OT-82 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | Unknown status | USA | 0 |
NCT03925935 | Phase I | AB-205 | Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation | Completed | USA | 0 |
NCT03930953 | Phase I | CC-99282 CC-99282 + Rituximab | A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Subjects With Relapsed or Refractory Non-hodgkin Lymphomas (R/R NHL) | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DNK | CAN | BRA | BEL | AUT | ARG | 3 |
NCT03938987 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD19 CAR-T cells | Anti-CD19, Dual Co-stimulatory (4-1BB, CD3zeta) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) | Recruiting | CAN | 0 |
NCT03983668 | Phase Ib/II | Pembrolizumab + Vidutolimod | CMP-001 for Relapsed and Refractory Lymphoma | Active, not recruiting | USA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04029038 | Phase Ib/II | CD19/CD22 CAR T cells | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma | Withdrawn | USA | 0 |
NCT04035434 | Phase Ib/II | CTX110 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies | Active, not recruiting | USA | FRA | ESP | DEU | CAN | AUS | 0 |
NCT04038359 | Phase II | Duvelisib | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma. (TEMPO) | Completed | USA | POL | ITA | GBR | DEU | CZE | 2 |
NCT04045028 | Phase I | Tiragolumab Daratumumab + Tiragolumab Rituximab + Tiragolumab | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Terminated | USA | 1 |
NCT04068597 | Phase Ib/II | CCS1477 | Study to Evaluate CCS1477 in Haematological Malignancies | Recruiting | USA | SWE | GBR | FRA | ESP | 0 |
NCT04074330 | Phase Ib/II | Rituximab + Subasumstat | A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT04089527 | Phase I | FT-1101 | Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma | Completed | FRA | ESP | 0 |
NCT04136756 | Phase I | NKTR-255 Daratumumab + NKTR-255 | NKTR-255 in Relapsed/Refractory Multiple Myeloma and Non Hodgkin Lymphoma and Combined With Daratumumab for Multiple Myeloma | Completed | USA | 0 |
NCT04161118 | Phase II | huCART19 | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (TIGER-CTL019) | Terminated | DEU | 0 |
NCT04205409 | Phase II | Nivolumab | Nivolumab for the Treatment of Relapsed or Refractory Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT04220008 | Phase II | Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Rituximab + Tacrolimus + Vorinostat Busulfan + Clofarabine + Cyclophosphamide + Gemcitabine + Mycophenolate mofetil + Tacrolimus + Vorinostat | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | Withdrawn | 0 | |
NCT04233697 | Phase I | Copanlisib + Romidepsin | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | Withdrawn | 0 | |
NCT04240704 | Phase I | JBH492 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | Terminated | ISR | FIN | ESP | DEU | 3 |
NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | NZL | ITA | GBR | ESP | DEU | AUS | 0 |
NCT04323657 | Phase Ib/II | Cyclophosphamide + Fludarabine TC-110 T-cells | TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT04328844 | Phase I | IOA-244 | A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers | Active, not recruiting | ITA | GBR | 0 |
NCT04331119 | Phase II | Duvelisib | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas | Active, not recruiting | USA | 0 |
NCT04341181 | Phase II | Atezolizumab Niraparib Erlotinib Axitinib Cobimetinib + Vemurafenib Avelumab Pertuzumab + Trastuzumab Vismodegib Alectinib Ado-trastuzumab emtansine | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (ProTarget) | Recruiting | DNK | 0 |
NCT04390737 | Phase I | HH2853 | A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853. | Recruiting | USA | 1 |
NCT04401020 | Phase I | SAR442257 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | Active, not recruiting | USA | NOR | ESP | CZE | 1 |
NCT04500587 | Phase I | ZN-d5 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | Completed | POL | HRV | ESP | BGR | AUS | 2 |
NCT04543305 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT04545762 | Phase I | Anti-CD19 CAR-T cells Cyclophosphamide + Fludarabine | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04663347 | Phase Ib/II | Epcoritamab-bysp Cisplatin + Cytarabine + Dexamethasone + Epcoritamab-bysp + Rituximab Epcoritamab-bysp + Gemcitabine + Oxaliplatin Epcoritamab-bysp + Lenalidomide + Rituximab Bendamustine + Epcoritamab-bysp + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2) | Recruiting | USA | SWE | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | CZE | BEL | AUS | 0 |
NCT04673617 | Phase Ib/II | AB-101 + Bendamustine + Rituximab AB-101 + Rituximab | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT04684108 | Phase I | SG301 | SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies | Active, not recruiting | 1 | |
NCT04684563 | Phase I | HuCART19-IL18 | huCART19-IL18 in NHL/CLL Patients | Recruiting | USA | 0 |
NCT04702425 | Phase I | MIK665 + VOB560 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | Terminated | USA | ITA | ISR | FIN | ESP | BEL | 3 |
NCT04703686 | Phase II | Glofitamab-gxbm + Obinutuzumab | Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | Active, not recruiting | FRA | 0 |
NCT04718675 | Phase I | KB-0742 | A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | Recruiting | USA | GBR | ESP | 0 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04730349 | Phase Ib/II | Nivolumab + NKTR-214 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020) | Terminated | USA | ITA | FRA | ESP | DEU | AUS | 0 |
NCT04739293 | Phase I | Narazaciclib | Study of ON 123300 in Patients With Advanced Cancer | Recruiting | USA | 0 |
NCT04756726 | Phase Ib/II | CFT7455 CFT7455 + Dexamethasone | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Recruiting | USA | 0 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04806035 | Phase I | TG-1801 + Ublituximab TG-1801 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | Terminated | USA | 0 |
NCT04827862 | Phase II | Pembrolizumab | RADVAX for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy | Recruiting | USA | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Active, not recruiting | FRA | BEL | 0 |
NCT04851119 | Phase Ib/II | BC2059 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Recruiting | USA | 0 |
NCT04853329 | Phase Ib/II | CPO107 | Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma | Suspended | USA | 0 |
NCT04860466 | Phase I | CC-96673 | A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Terminated | USA | FRA | ESP | CAN | 0 |
NCT04876092 | Phase I | Ibrutinib + JNJ-67856633 | A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in B-cell NHL and CLL | Active, not recruiting | SWE | POL | FRA | DNK | 0 |
NCT04892277 | Phase I | Bendamustine IC19/1563 Cyclophosphamide + Fludarabine | CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Recruiting | USA | 0 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04903197 | Phase I | Lenalidomide + VAY736 VAY736 | Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma | Active, not recruiting | ITA | DEU | AUS | 4 |
NCT04920383 | Phase I | ALPN-202 + unspecified PD-1 antibody | ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NEON-2) | Terminated | USA | 0 |
NCT04970901 | Phase I | Loncastuximab tesirine-lpyl + Umbralisib Lenalidomide + Loncastuximab tesirine-lpyl Loncastuximab tesirine-lpyl + Polatuzumab vedotin-piiq Gemcitabine + Loncastuximab tesirine-lpyl | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7) | Recruiting | USA | ITA | GBR | ESP | CZE | BEL | 0 |
NCT04986865 | Phase I | ATG-101 | A Study of Evaluating the Safety and Efficacy of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE) | Recruiting | USA | AUS | 0 |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Unknown status | USA | AUS | 1 |
NCT05005299 | Phase I | Cyclophosphamide + Fludarabine + Venetoclax | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) | Recruiting | AUS | 0 |
NCT05005442 | Phase II | MK-7684A | A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004) | Active, not recruiting | USA | TUR | POL | ITA | ISR | HUN | FRA | ESP | DNK | DEU | CAN | BRA | 4 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | AUS | 0 |
NCT05025800 | Phase Ib/II | Evorpacept + Lenalidomide + Rituximab | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05040932 | Phase I | YH004 | Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy | Completed | AUS | 0 |
NCT05044039 | Phase I | Duvelisib | Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy | Recruiting | USA | 0 |
NCT05053659 | Phase I | Loncastuximab tesirine-lpyl + Venetoclax | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05134740 | Phase I | MultiTAA-specific T cells | (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). | Withdrawn | USA | 0 |
NCT05144334 | Phase I | BTX-1188 | A Study of BTX-1188 in Subjects With Advanced Malignancies | Terminated | USA | 0 |
NCT05144347 | Phase I | XL114 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Terminated | USA | 0 |
NCT05169515 | Phase I | Glofitamab-gxbm + Iberdomide CC-99282 + Glofitamab-gxbm CC-99282 + Mosunetuzumab-axgb Iberdomide + Mosunetuzumab-axgb | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | ITA | ISR | GBR | ESP | 0 |
NCT05169658 | Phase II | Mosunetuzumab-axgb + Obinutuzumab + Polatuzumab vedotin-piiq | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT05171647 | Phase III | Mosunetuzumab-axgb + Polatuzumab vedotin-piiq Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Tocilizumab Gemcitabine + Oxaliplatin + Rituximab | A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (SUNMO) | Active, not recruiting | USA | TUR | NZL | ISR | CAN | BRA | ARG | 6 |
NCT05181540 | Phase III | AB-205 | A Phase 3 Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (E-CELERATE) | Terminated | USA | 0 |
NCT05191225 | FDA approved | Rituximab | Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study | Unknown status | ESP | 0 |
NCT05202782 | Phase II | Zanubrutinib | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | Active, not recruiting | USA | 0 |
NCT05205161 | Phase Ib/II | AZD0466 | A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma | Terminated | USA | ITA | FRA | ESP | AUS | 2 |
NCT05253495 | Phase II | Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Rituximab + Vincristine Sulfate Cyclophosphamide + Dexamethasone + Vincristine Sulfate Cytarabine + Etoposide + Polatuzumab vedotin-piiq + Rituximab Cytarabine + Etoposide + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Hydrocortisone Sodium Succinate + Methotrexate + Polatuzumab vedotin-piiq + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Nivolumab + Rituximab + Vinblastine Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine Cytarabine + Methotrexate + Rituximab Brentuximab vedotin + Dacarbazine + Doxorubicin + Rituximab + Vinblastine Cyclophosphamide + Doxorubicin + Polatuzumab vedotin-piiq | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (RADICAL) | Recruiting | USA | 0 |
NCT05255601 | Phase Ib/II | Nivolumab + Relatlimab | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05272384 | Phase I | Decitabine and Cedazuridine + Nivolumab | Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05275504 | Phase I | TT-01488 | Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | Unknown status | USA | 0 |
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | AUS | 1 |
NCT05293912 | Phase I | SG2501 | SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. | Recruiting | USA | 0 |
NCT05312801 | Phase I | LMY-920 | Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05336409 | Phase I | CNTY-101 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1) | Recruiting | USA | 0 |
NCT05346809 | Phase II | Isatuximab | Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma | Recruiting | USA | 0 |
NCT05348889 | Phase Ib/II | 1A46 | First-in-Human (FIH) Trial of 1A46 in Subjects With Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT05365659 | Phase I | IKS03 | IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas | Recruiting | USA | ITA | ESP | CAN | AUS | 0 |
NCT05377827 | Phase I | WU-CART-007 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT05389423 | Phase I | Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Pomalidomide + Prednisone + Rituximab + Vincristine Sulfate | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | Suspended | USA | 0 |
NCT05397496 | Phase I | PIT565 | Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | Recruiting | USA | ITA | ISR | FRA | ESP | BEL | 2 |
NCT05400109 | Phase I | Cyclophosphamide + Fludarabine UF-KURE19 | Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas | Active, not recruiting | USA | 0 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05415098 | Phase I | APG-5918 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05418088 | Phase I | Cyclophosphamide + Fludarabine Anti-CD19/CD20/CD22 CAR-T Cells | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies | Recruiting | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | POL | ISR | FRA | DNK | AUS | 2 |
NCT05453396 | Phase II | Loncastuximab tesirine-lpyl | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Recruiting | USA | 0 |
NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT05515406 | Phase I | ONO-7018 | A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL | Recruiting | USA | 0 |
NCT05533775 | Phase Ib/II | Glofitamab-gxbm Carboplatin + Etoposide + Glofitamab-gxbm + Ifosfamide + Rituximab Tocilizumab Obinutuzumab | A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO) | Recruiting | USA | ITA | FRA | ESP | DNK | DEU | AUS | 1 |
NCT05537766 | Phase II | Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) | Active, not recruiting | USA | NLD | ITA | FRA | ESP | DEU | CHE | AUT | 0 |
NCT05588440 | Phase Ib/II | Cyclophosphamide + Fludarabine ONCT-808 | A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies | Terminated | USA | 0 |
NCT05607420 | Phase Ib/II | Alemtuzumab UCART20X22 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) | Recruiting | USA | FRA | ESP | 0 |
NCT05618925 | Phase I | Cyclophosphamide + Fludarabine CD19 t-haNK cells + Rituximab CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab | Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05653271 | Phase I | ACE1831 + Cyclophosphamide + Fludarabine + Obinutuzumab ACE1831 + Cyclophosphamide + Fludarabine | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | Recruiting | USA | 1 |
NCT05665062 | Phase I | Cyclophosphamide + Fludarabine STK-009 + SYNCAR-001 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | Recruiting | USA | 0 |
NCT05665725 | Phase I | Siltuximab | Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT05678998 | Phase I | WTX-330 | WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05681195 | Phase II | Pemetrexed Disodium + Zanubrutinib | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | Recruiting | USA | 0 |
NCT05685173 | Phase I | Odronextamab + REGN5837 | A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Participants With Aggressive B-cell Non-Hodgkin Lymphomas (ATHENA-1) | Recruiting | USA | NLD | GBR | FRA | ESP | 0 |
NCT05721222 | Phase Ib/II | PRO1160 | PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001) | Recruiting | USA | 1 |
NCT05737628 | Phase I | BYON4228 + Rituximab | First-in-human Dose Escalation and Expansion Study With the SIRPalpha-directed Monoclonal Antibody BYON4228 | Recruiting | NLD | ITA | GBR | ESP | 0 |
NCT05753501 | Phase I | ABBV-101 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Recruiting | USA | ISR | GBR | FRA | ESP | DEU | CAN | 1 |
NCT05755087 | Phase I | BC2059 | Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma | Recruiting | USA | 0 |
NCT05779930 | Phase I | Anti-CD19 CAR-T cells | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | Not yet recruiting | USA | 0 |
NCT05784441 | Phase I | JNJ-90009530 | A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) | Recruiting | USA | ISR | GBR | AUS | 0 |
NCT05798897 | Phase I | MT-601 | Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO) | Recruiting | USA | 0 |
NCT05801913 | Phase I | CMV-CD19 CAR T-cells + Multi-antigen CMV-modified vaccinia Ankara vaccine | Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT05824585 | Phase I | DZD8586 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | AUS | 0 |
NCT05826535 | Phase Ib/II | IMPT-314 | Study of IMPT-314 in R/R Aggressive B-cell | Recruiting | USA | 0 |
NCT05828589 | Phase I | BGB-21447 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | Recruiting | AUS | 1 |
NCT05878184 | Phase I | Cyclophosphamide + Fludarabine SC291 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | Active, not recruiting | USA | AUS | 0 |
NCT05892718 | Phase I | HCB101 | A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPa-CD47 Pathway, in Solid or Hematological Tumors | Recruiting | USA | 1 |
NCT05950165 | Phase Ib/II | CHO-H01 + Lenalidomide CHO-H01 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | Recruiting | USA | 1 |
NCT05950334 | Phase I | Bendamustine + FT522 + Rituximab Cyclophosphamide + Fludarabine + FT522 + Rituximab FT522 + Rituximab | FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) | Recruiting | USA | 0 |
NCT05963217 | Phase I | Cyclophosphamide + Fludarabine TBI-2001 | Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL | Recruiting | CAN | 0 |
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT05991388 | Phase II | Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Loncastuximab tesirine-lpyl + Rituximab Odronextamab Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL) | Recruiting | GBR | 0 |
NCT05994157 | Phase I | CD38-SADA + Lutetium Lu 177-DOTA | Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06028373 | Phase I | ATG-031 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | Recruiting | USA | 0 |
NCT06045910 | Phase Ib/II | ALETA-001 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | Recruiting | GBR | 0 |
NCT06098651 | Phase I | DCR-STAT3 | A Study of DCR-STAT3 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06101381 | Phase Ib/II | huCART19 | CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma (CARTHEDRALL) | Not yet recruiting | BRA | 0 |
NCT06119685 | Phase Ib/II | IDP-023 Cyclophosphamide + Fludarabine Daratumumab + IDP-023 Aldesleukin + IDP-023 IDP-023 + Rituximab | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Recruiting | USA | 0 |
NCT06132503 | Phase I | LP-284 | A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors | Recruiting | USA | 0 |
NCT06173518 | Phase I | Obecabtagene autoleucel | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | Recruiting | USA | GBR | ESP | 0 |
NCT06176690 | Phase I | C7R.CD30.CAR-EBVS T-cells | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas | Not yet recruiting | USA | 0 |
NCT06188208 | Phase I | Pembrolizumab + VVD-130850 VVD-130850 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | Recruiting | USA | ESP | AUS | 0 |
NCT06191887 | Phase I | Bendamustine BAFFR-CAR T cells Cyclophosphamide + Fludarabine | B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Recruiting | USA | 0 |
NCT06209619 | Phase I | CC-99282 + Rituximab | CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT06227026 | Phase I | Anti-CD19 CAR-T cells | Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY) | Recruiting | USA | 0 |
NCT06230224 | Phase III | Carboplatin + Etoposide + Ifosfamide Carboplatin + Etoposide + Ifosfamide + Rituximab Cisplatin + Dexamethasone + Gemcitabine + Rituximab Cisplatin + Cytarabine + Dexamethasone Cisplatin + Dexamethasone + Gemcitabine Odronextamab Cisplatin + Cytarabine + Dexamethasone + Rituximab | A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4) | Recruiting | TUR | NLD | ITA | ESP | AUS | 5 |
NCT06242834 | Phase II | Pembrolizumab + Tazemetostat | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | Recruiting | USA | 0 |
NCT06256484 | Phase I | ATA3219 | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |
NCT06343311 | Phase Ib/II | EB103 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1) | Recruiting | USA | 0 |
NCT06392477 | Phase I | DR-0201 | A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | AUS | 5 |
NCT06393738 | Phase I | ARV-393 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | Recruiting | USA | ESP | DNK | CAN | 0 |
NCT06470438 | Phase I | JNJ-88998377 | A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Recruiting | TUR | POL | ITA | 4 |
NCT06504368 | Phase I | DCR-PDL1 | Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06534437 | Phase II | Glofitamab-gxbm Glofitamab-gxbm + SEL24-B489 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) (JASPIS-01) | Not yet recruiting | POL | 0 |
NCT06536049 | Phase Ib/II | Epcoritamab-bysp + Ibrutinib | Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | Not yet recruiting | USA | 0 |
NCT06539338 | Phase I | INT2104 | Safety of INT2104 in Participants Aged 18 Years and Older Who Have B-cell Cancer That Came Back After Prior Treatment (INVISE) | Recruiting | AUS | 0 |
NCT06578624 | Phase Ib/II | SA53-OS | Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | USA | 0 |
NCT06594939 | Phase II | Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Polatuzumab vedotin-piiq + Prednisone Pegfilgrastim Cyclophosphamide + Doxorubicin + Mosunetuzumab-axgb + Prednisone | Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma | Not yet recruiting | USA | 0 |